钇90放射微球与抗肿瘤药物治疗肝癌的临床进展

Clinical Progress of Yttrium 90 Radiation Microspheres and Antitumor Drugs in the Treatment of Liver Cancer

摘要: 目前我国仍然是乙肝大国，乙肝、肝硬化、肝癌是肝癌发展的“三部曲”。肝癌是我国发病率较高的恶性肿瘤之一，预后差、生存期短。肝恶性肿瘤严重威胁着我国人民的身体健康，给个人、家庭和社会带来严重的经济负担。由于肝癌发病隐匿，大多数患者就诊时已经处于晚期，丧失手术治疗的机会。对于晚期不可切除肝癌可选择系统抗肿瘤药物、TACE、放疗、化疗等治疗方式。钇90作为肝癌内放疗的一种治疗方法，已经在国外开展的比较成熟。随着钇90放射微球在我国的批准上市，国内各大医院正在积极开展钇90放射微球对晚期不可切除肝癌的治疗。本文就钇90放射微球和系统抗肿瘤药物治疗肝癌的效果做一综述。

Abstract: At present, China is still a big country of hepatitis B, hepatitis B, cirrhosis, liver cancer is the “trilo-gy” of liver cancer development. Hepatocellular carcinoma is one of the malignant tumors with high incidence in China, with poor prognosis and short survival time. Liver malignant tumor is a serious threat to the health of our people, and brings serious economic burden to individuals, families and society. Due to the occult onset of liver cancer, most patients are already in the advanced stage of treatment and lose the opportunity of surgical treatment. For patients with advanced unresectable liver cancer, systematic antitumor drugs, TACE, radiotherapy, chemotherapy and other treatment methods can be selected. Yttrium 90 has been developed in foreign countries as a kind of internal radiotherapy for liver cancer. With the approval of Yttrium 90 radiation microspheres in China, major hospitals in China are actively carrying out Yttrium 90 radiation microspheres for the treat-ment of advanced unresectable liver cancer. This article reviews the effects of Yttrium 90 radiation microspheres and systematic antitumor drugs on hepatocarcinoma.